PMID- 29315963
OWN - NLM
STAT- MEDLINE
DCOM- 20190422
LR  - 20221207
IS  - 1099-1611 (Electronic)
IS  - 1057-9249 (Linking)
VI  - 27
IP  - 4
DP  - 2018 Apr
TI  - Distinct and heterogeneous trajectories of self-perceived cognitive impairment 
      among Asian breast cancer survivors.
PG  - 1185-1192
LID - 10.1002/pon.4635 [doi]
AB  - OBJECTIVES: Currently, there are no studies that have established the 
      self-perceived cognitive trajectories experienced by breast cancer patients 
      (BCPs) post-chemotherapy. Therefore, we characterized the long-term trajectory of 
      self-perceived cognitive function among Asian early-stage BCPs using the minimal 
      clinically important difference of a subjective measure of cognitive function. 
      METHODS: Early-stage BCPs who received chemotherapy were recruited and assessed 
      at 4 time points: Before chemotherapy initiation (T1), 6 weeks post-chemotherapy 
      initiation (T2), 12 weeks post-chemotherapy initiation (T3), and 15-months 
      post-chemotherapy initiation (T4). All assessments were performed approximately 
      within 2 weeks post-chemotherapy. Subjective and objective cognitive function 
      were assessed using Functional Assessment of Cancer Therapy-Cognitive (version 3) 
      and Headminder. RESULTS: A total of 166 BCPs were recruited, of whom 131 
      completed assessment at all time points. Using the minimal clinically important 
      difference of Functional Assessment of Cancer Therapy-Cognitive, 5 distinct 
      cognitive trajectories were established. Of the 131 patients, 70 (53.4%) did not 
      report any clinically significant cognitive impairment. Twenty-one (16.0%) 
      patients reported acute cognitive changes during chemotherapy (T2 and/or T3) but 
      not at T4. Forty patients (30.5%) reported clinically significant cognitive 
      impairment at T4, of whom 18 did not report any cognitive impairment at earlier 
      time points. Fifteen (11.5%) patients reported persistent cognitive impairment 
      throughout all time points, while 7 (5.3%) patients reported intermittent 
      cognitive impairment at T2 and T4 but not at T3. CONCLUSION: This is the first 
      study to establish the existence of heterogeneous cognitive trajectories based on 
      clinically significant thresholds of self-perceived cognitive impairment. The 
      findings have important implications on the window for screening and management 
      of post-chemotherapy cognitive impairment.
CI  - Copyright (c) 2018 John Wiley & Sons, Ltd.
FAU - Ng, Terence
AU  - Ng T
AUID- ORCID: 0000-0002-3252-017X
AD  - Department of Pharmacy, National University of Singapore, Singapore.
AD  - Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
FAU - Dorajoo, Sreemanee Raaj
AU  - Dorajoo SR
AD  - Department of Pharmacy, National University of Singapore, Singapore.
FAU - Cheung, Yin Ting
AU  - Cheung YT
AD  - Department of Pharmacy, National University of Singapore, Singapore.
FAU - Lam, Yick Ching
AU  - Lam YC
AD  - Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
FAU - Yeo, Hui Ling
AU  - Yeo HL
AD  - Department of Pharmacy, National University of Singapore, Singapore.
FAU - Shwe, Maung
AU  - Shwe M
AD  - Department of Pharmacy, National University of Singapore, Singapore.
FAU - Gan, Yan Xiang
AU  - Gan YX
AD  - Department of Pharmacy, National Cancer Centre Singapore, Singapore.
FAU - Foo, Koon Mian
AU  - Foo KM
AD  - Department of Pharmacy, KK Women's and Children's Hospital, Singapore.
FAU - Loh, Wei-Jen Kiley
AU  - Loh WK
AD  - Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
FAU - Koo, Si-Lin
AU  - Koo SL
AD  - Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
FAU - Jain, Amit
AU  - Jain A
AD  - Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
FAU - Lee, Guek Eng
AU  - Lee GE
AD  - Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
FAU - Dent, Rebecca
AU  - Dent R
AD  - Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
AD  - Duke-NUS Graduate Medical School Singapore, Singapore.
FAU - Yap, Yoon Sim
AU  - Yap YS
AD  - Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
FAU - Ng, Raymond
AU  - Ng R
AD  - Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
AD  - Duke-NUS Graduate Medical School Singapore, Singapore.
FAU - Chan, Alexandre
AU  - Chan A
AUID- ORCID: 0000-0003-4391-4219
AD  - Department of Pharmacy, National University of Singapore, Singapore.
AD  - Department of Pharmacy, National Cancer Centre Singapore, Singapore.
AD  - Duke-NUS Graduate Medical School Singapore, Singapore.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180201
PL  - England
TA  - Psychooncology
JT  - Psycho-oncology
JID - 9214524
SB  - IM
MH  - Adult
MH  - Aged
MH  - Asian People/*psychology
MH  - Breast Neoplasms/*psychology
MH  - Cancer Survivors/*psychology
MH  - Cognition
MH  - Cognitive Dysfunction/*psychology
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Middle Aged
MH  - Prospective Studies
MH  - *Self Concept
MH  - Singapore
OTO - NOTNLM
OT  - breast cancer
OT  - cancer
OT  - chemotherapy
OT  - cognition
OT  - oncology
EDAT- 2018/01/10 06:00
MHDA- 2019/04/23 06:00
CRDT- 2018/01/10 06:00
PHST- 2017/08/02 00:00 [received]
PHST- 2017/12/20 00:00 [revised]
PHST- 2017/12/29 00:00 [accepted]
PHST- 2018/01/10 06:00 [pubmed]
PHST- 2019/04/23 06:00 [medline]
PHST- 2018/01/10 06:00 [entrez]
AID - 10.1002/pon.4635 [doi]
PST - ppublish
SO  - Psychooncology. 2018 Apr;27(4):1185-1192. doi: 10.1002/pon.4635. Epub 2018 Feb 1.